|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MART-1 mRNA-positive cells were also detected in tumor-negative SN sections from 6 of 7 (86%) nodes that had tumor present in areas of the node not represented in the studied sections.
|
21997686 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes (TIL) from melanoma patients.
|
7868898 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
|
18097665 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.
|
11466335 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After an initial period of tumor regression, the patient presented in relapse with tumors lacking melanocytic antigens (MART1, gp100) and expressing an inflammation-induced neural crest marker (NGFR).
|
29899062 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although a series of melanoma differentiation antigens for immunotherapeutic targeting has been described, heterogeneous expression of antigens such as Melan-A/MART-1 and gp100 results from a loss of antigenic expression in many late stage tumors.
|
22085019 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of the small round blue cell morphology and negative immunohistochemical staining for pan-melanocytic cocktail (HMB45, anti MART1 and anti-tyrosinase) and SOX10 in both cases, FLI-1 immunostaining was requested as part of the tumors workup.
|
28605142 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By using quantitative real-time PCR, gene expressions of cytokines (IL-4, IL-10, IFNγ, TGFβ, GM-CSF) and the surrogates of immunosuppressive regulatory and effector cells (IDO-expressing DCs and Foxp3-expressing T-regs, respectively) were measured and correlated against the SLN tumor burden (MART1) and against each other.
|
21327637 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clone DMF5, from a TIL infusion that mediated tumor regression clinically, showed the highest avidity against MART-1 expressing tumors in vitro, both endogenously in the TIL clone, and after RNA electroporation into donor T cells.
|
17056587 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
|
10687150 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In 321 patients we obtained data on SLN microanatomic location/tumor burden (only 7 cases had metastases <0.1 mm); in 137 we additionally analyzed 24-hour collected LY after CLND (multimarker reverse transcriptase-polymerase chain reaction [MM-RT-PCR] with primers for tyrosinase, MART1 (MelanA), and uMAGE mRNA (27.7% positive samples)].Median follow-up time was 41 months.
|
20607422 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
|
21159666 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No expression of the MART-1 gene was observed in any cell line or tumor sample.
|
8900375 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathologic response and loss of the Melan-A/MART-1 antigen were evidenced on residual tumor removed in April 2012.
|
25880253 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The "antigen loss" could be restored in the variant tumor cell line by simultaneously providing both the MART-1/Melan-A gene (by retroviral transfer) and the TAP-1 gene (by a bioballistic approach) resulting in tumor cell sensitivity to MART-1/Melan-A-specific cytotoxic T lymphocytes.
|
8833913 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor-associated-Ag MART-1 is expressed by most human melanomas.
|
10384155 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The MART-1/Melan-A human melanoma tumor antigen can be recognized by T lymphocytes and appears to be involved in tumor regression.
|
9218710 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data demonstrate that tumor number in lnc-HUR1 transgenic mice is higher compared with control mice, indicating that lnc-HUR1 enhances diethylnitrosamine-induced tumorigenesis.
|
29790592 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The genes for the alpha and beta chains of a highly reactive anti-MART-1 T-cell receptor were isolated from T-lymphocytes that mediated in vivo regression of tumor in a patient with metastatic melanoma.
|
15871677 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was an increase in melanomaassociated antigen recognized by T cells (MART-1)-specific T cells in tumors undergoing regression after vaccination compared with T cells derived from melanoma patients not treated with vaccine.
|
19915919 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results demonstrate that hTERT-transduced human CTLs are capable of mediating antitumor activity in vivo in an antigen-specific manner. hTERT-transduced MART-1-specific CTL clones AKR4D8 and AKR103 inhibited the growth of syngeneic melAKR tumors in vivo.
|
15026357 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This represents a novel approach for potentially controlling tumor cell variants found in primary heterogeneous melanoma tumor cell populations that would normally escape killing by MART-1-specific immunotherapy.
|
11207317 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This transfected tumor [NFSA(MART1)] grows progressively in C3Hf/Kam/Sed (H-2k) mice.
|
9230191 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work evaluated the impact of surface modifications of mannosamine-conjugated multifunctional poly(glutamic acid) (PG)-dendrimers as nanocarriers of the tumour associated antigens (TAA) MART-1, gp100:44 and gp100:209.
|
28795601 |
2018 |